Is CRISPR Stock Heading to $160 in 2021?
CRISPR Therapeutics (NASDAQ: CRSP) is a stock with nearly 40% upside, according to a new analysis. Prognosticator Silvan Turkcan of JMP Group's JMP Securities has initiated coverage of the company with a market outperform (buy) recommendation at a $160 per share price target.
Gene editing, which is the core of CRISPR's business, is still a nascent industry with a great deal of potential. Turkcan described CRISPR's offerings as "powerful new bioengineering tools" that have a potentially very long reach. In addition to their obvious use in the medical field, they can also be used to concoct products such as biofuels and industrial materials.
Image source: Getty Images.
Source Fool.com
